Zobrazeno 1 - 10
of 182
pro vyhledávání: '"J, Zemla"'
Autor:
Elizabeth S. Nakasone, Tyler J. Zemla, Ming Yu, She Yu Lin, Fang-Shu Ou, Kelly Carter, Federico Innocenti, Leonard Saltz, William M. Grady, Stacey A. Cohen
Publikováno v:
Epigenetics, Vol 19, Iss 1 (2024)
ABSTRACTWhile epigenomic alterations are common in colorectal cancers (CRC), few epigenomic biomarkers that risk-stratify patients have been identified. We thus sought to determine the potential of ZNF331 promoter hypermethylation (mZNF331) as a prog
Externí odkaz:
https://doaj.org/article/9934e8c678554cc0aff190ec4294bfc1
Autor:
Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, Stacey A. Cohen
Publikováno v:
Epigenetics, Vol 17, Iss 12, Pp 1715-1725 (2022)
Aberrantly methylated genes contribute to the landscape of epigenetic alterations in colorectal adenocarcinoma. The global CpG Island methylator phenotype (CIMP) and individually methylated genes are potential prognostic/predictive biomarkers. Resear
Externí odkaz:
https://doaj.org/article/fedc615c145b49aa9716d591e2847ecb
Autor:
Jennifer J. Gile, Vanessa Wookey, Tyler J. Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts, Robert R. McWilliams, Wen Wee Ma, Mitesh Borad, Tanios S. Bekaii-Saab, Nguyen H. Tran, Amit Mahipal
Publikováno v:
Targeted Oncology. 17:529-538
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adbfdd219c77c61340af03b76e77db98
https://doi.org/10.1007/s11523-022-00914-w
https://doi.org/10.1007/s11523-022-00914-w
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag, Shaker R Dakhil, Philip J Stella, Douglas J Weckstein, Donald B Wender, Meredith Faggen, Tyler J Zemla, Erica N Heying, Samantha R Schuetz, Stephanie Noble, Jeffrey A Meyerhardt, Tanios Bekaii-Saab, Charles S Fuchs, Kimmie Ng
Publikováno v:
The Oncologist. 27:292-298
Background Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. Patients and Methods In this multicenter, randomized, double-blind, plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72600987018bd980d0825415a370f7a3
https://doi.org/10.1093/oncolo/oyab025
https://doi.org/10.1093/oncolo/oyab025
Autor:
Frank A. Sinicrope, Qian Shi, Aurelie Catteau, Graham M. Poage, Tyler J. Zemla, Bernhard Mlecnik, Al B. Benson, Sharlene Gill, Richard M. Goldberg, Morton S. Kahlenberg, Suresh G. Nair, Anthony F. Shields, Thomas C. Smyrk, Jerome Galon, Steven R. Alberts
Publikováno v:
JCO Precision Oncology.
PURPOSE The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T1-3 N1) and high-risk (T4 or N2) groups. We determined whe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed77c7c833d4abdc93a928c901640b00
https://doi.org/10.1200/po.22.00010
https://doi.org/10.1200/po.22.00010
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mathias Earl Palmer, Michael H. Storandt, Jennifer Gile, Tyler J. Zemla, Tanios S. Bekaii-Saab, Zhaohui Jin, Nguyen H. Tran, Amit Mahipal
Publikováno v:
Journal of Clinical Oncology. 41:559-559
559 Background: Cabozantinib, a multikanase inhibitor, is approved by the Food and Drug Administration (FDA) for treatment of advanced stage hepatocellular carcinoma (HCC) following progression on sorafenib. The CELESTIAL study which demonstrated ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b47b1d7cb0354539ad2636c77427544
https://doi.org/10.1200/jco.2023.41.4_suppl.559
https://doi.org/10.1200/jco.2023.41.4_suppl.559
Autor:
Joleen M. Hubbard, Tyler J. Zemla, Rondell P. Graham, Zhaohui Jin, Mojun Zhu, Jessica L. Mitchell, Elise Novo, Eva Vegh, Orsolya Lorincz, Mariann Kremlitzka, Eszter Somogyi, Levente Molnar, József Tóth, Eniko Rita Toke
Publikováno v:
Journal of Clinical Oncology. 41:147-147
147 Background: PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine containing 12 immunogenic epitopes derived from 7 cancer testis antigens (CTAs) frequently expressed in patients with colorectal cancer (CRC). PolyPEPI1018 successfully induced a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33f0524b0c7cda739e7fca2f12ae9131
https://doi.org/10.1200/jco.2023.41.4_suppl.147
https://doi.org/10.1200/jco.2023.41.4_suppl.147
Autor:
Michael H. Storandt, Oluwadunni Eunice Emiloju, Tyler J. Zemla, Robert R. McWilliams, Frank A. Sinicrope, Jessica L. Mitchell, Qian Shi, Zhaohui Jin
Publikováno v:
Journal of Clinical Oncology. 41:227-227
227 Background: Circulating tumor DNA (ctDNA) consists of small fragments of DNA released into the plasma from cancer cells. Tumor informed ctDNA testing by whole exome sequencing of the primary tumor coupled with multiplex polymerase chain reaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1a3819cd1347bfd8b3becf79e135fd3
https://doi.org/10.1200/jco.2023.41.4_suppl.227
https://doi.org/10.1200/jco.2023.41.4_suppl.227